Pharmaceutical Products Price Equity Act

The Pharmaceutical Products Price Equity Act (H.R. 4850) would require the President to establish regulations ensuring that prescription drugs sold in the United States are not significantly more expensive than they are abroad. Specifically, the bill would cap the retail price of any pharmaceutical product at no more than 6% above the average price found in the world’s five most industrialized free-market countries.

For American consumers, this legislation aims to lower out-of-pocket costs by aligning domestic drug prices with international standards. The bill includes enforcement mechanisms and civil liability provisions to ensure pharmaceutical companies comply with these pricing limits.